Patents by Inventor Javad M. Zadei

Javad M. Zadei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable amorphous amifostine compositions and methods for the preparation and use of same
    Patent number: 7629333
    Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: December 8, 2009
    Assignee: MedImmune, LLC
    Inventors: Martin Stogniew, Javad M. Zadei
  • ANALYSIS OF POLYPEPTIDE PRODUCTION
    Publication number: 20090035807
    Abstract: The present invention is directed to methods of evaluating a process to produce a polypeptide preparation or evaluating an element of a process to produce a polypeptide preparation. The methods comprise providing a sample comprising the polypeptide, wherein the sample has not been subjected to affinity chromatography, and subjecting the sample to liquid chromatography. The sample may be a process bioreactor sample. The methods of the invention may be used to determine a value of a characteristic of the sample. The methods of the invention provide a real time or near real-time information regarding the process to produce a polypeptide.
    Type: Application
    Filed: July 30, 2008
    Publication date: February 5, 2009
    Applicant: Wyeth
    Inventors: Joseph Edward McCellan, Jason Craig Rouse, Jason Eric Lieske, Javad M. Zadei
  • Stable amorphous amifostine compositions and methods for the preparation of same
    Patent number: 6841545
    Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: January 11, 2005
    Assignee: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei
  • Novel compositions comprising trimetrexate and methods of their synthesis and use
    Publication number: 20030216418
    Abstract: This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of diseases in mammals such as, but not limited to, cancer, bacterial and protozoal infections, malaria, psoriasis, and rheumatoid arthritis. The invention is further related to methods of stabilizing trimetrexate to degradation caused by heat, light, oxygen, or water.
    Type: Application
    Filed: June 10, 2003
    Publication date: November 20, 2003
    Applicant: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei
  • Compositions comprising trimetrexate
    Patent number: 6576635
    Abstract: This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of diseases in mammals such as, but not limited to, cancer, bacterial and protozoal infections, malaria, psoriasis, and rheumatoid arthritis. The invention is further related to methods of stabilizing trimetrexate to degradation caused by heat, light, oxygen, or water.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: June 10, 2003
    Assignee: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei
  • Novel pharmaceutical formulations comprising aminoalkyl phosphorothioates
    Publication number: 20030096797
    Abstract: The present invention provides novel pharmaceutical compositions comprising aminoalkyl phosphorothioate compounds in combination with surfactants, hydrotropes and chelating agents. The compositions are well-suited for subcutaneous administration.
    Type: Application
    Filed: September 26, 2002
    Publication date: May 22, 2003
    Applicant: MedImmune Oncology
    Inventors: Martin Stogniew, Javad M. Zadei
  • Pharmaceutical formulations comprising aminoalkyl phosphorothioates
    Patent number: 6489312
    Abstract: The present invention provides novel pharmaceutical compositions comprising aminoalkyl phosphorothioate compounds in combination with surfactants, hydrotropes and chelating agents. The compositions are well-suited for subcutaneous administration.
    Type: Grant
    Filed: June 15, 1999
    Date of Patent: December 3, 2002
    Assignee: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei
  • Stable amorphous amifostine compositions and methods for the preparation of same
    Publication number: 20020147180
    Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.
    Type: Application
    Filed: March 29, 2002
    Publication date: October 10, 2002
    Applicant: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei
  • Stable amorphous amifostine compositions and methods for the preparation and use of the same
    Patent number: 6407278
    Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: June 18, 2002
    Assignee: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei
  • Stable amorphous amifostine compositions and dosage form
    Patent number: 6384259
    Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: May 7, 2002
    Assignee: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei
  • Novel compositions comprising trimetrexate
    Publication number: 20010031755
    Abstract: This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of diseases in mammals such as, but not limited to, cancer, bacterial and protozoal infections, malaria, psoriasis, and rheumatoid arthritis. The invention is further related to methods of stabilizing trimetrexate to degradation caused by heat, light, oxygen, or water.
    Type: Application
    Filed: May 21, 2001
    Publication date: October 18, 2001
    Applicant: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei
  • Compositions comprising trimetrexate and methods of their synthesis and use
    Patent number: 6258821
    Abstract: This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of diseases in mammals such as, but not limited to, cancer, bacterial and protozoal infections, malaria, psoriasis, and rheumatoid arthritis. The invention is further related to methods of stabilizing trimetrexate to degradation caused by heat, light, oxygen, or water.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: July 10, 2001
    Assignee: MedImmune Oncology, Inc.
    Inventors: Martin Stogniew, Javad M. Zadei